FMC1-LUC7L2

Across TCGA pan-cancer cohorts, FMC1-LUC7L2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FMC1-LUC7L2 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher FMC1-LUC7L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FMC1-LUC7L2 expression acts as an unfavorable survival marker.

LGG are the cancer types where FMC1-LUC7L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	OS	Median	All	0.147	0.811	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

FMC1-LUC7L2–LGG (OS)

Open the LGG breakdown →